SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy
Authors:
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 37 (6) , 834-849.e13
Abstract
No abstract availableKeywords
Funding Information
- Stanford University
- University of Texas MD Anderson Cancer Center
This publication has 70 references indexed in Scilit:
- The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinomaNature, 2012
- Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinomaProceedings of the National Academy of Sciences, 2012
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cellsNature Chemical Biology, 2011
- A conditional knockout resource for the genome-wide study of mouse gene functionNature, 2011
- Chemical Probes Identify a Role for Histone Deacetylase 3 in Friedreich's Ataxia Gene SilencingChemistry & Biology, 2009
- Rapid creation and quantitative monitoring of high coverage shRNA librariesNature Methods, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- ING2 PHD domain links histone H3 lysine 4 methylation to active gene repressionNature, 2006
- Both p16 Ink4a and the p19 Arf -p53 pathway constrain progression of pancreatic adenocarcinoma in the mouseProceedings of the National Academy of Sciences, 2006